Loading...

Kuros Biosciences

DB:YTSN
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
YTSN
DB
CHF37M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the Kingdom of Saudi Arabia, and internationally. The last earnings update was 7 days ago. More info.


Add to Portfolio Compare Print
  • Kuros Biosciences has significant price volatility in the past 3 months.
YTSN Share Price and Events
7 Day Returns
-7.9%
DB:YTSN
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-74.8%
DB:YTSN
-10.6%
DE Biotechs
-6.2%
DE Market
YTSN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Kuros Biosciences (YTSN) -7.9% -9.9% 7.5% -74.8% -90.7% -
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • YTSN underperformed the Biotechs industry which returned -10.6% over the past year.
  • YTSN underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
YTSN
Industry
5yr Volatility vs Market

Value

 Is Kuros Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Kuros Biosciences. This is due to cash flow or dividend data being unavailable. The share price is €2.09.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Kuros Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Kuros Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:YTSN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in CHF CHF-1.34
SWX:KURN Share Price ** SWX (2019-04-18) in CHF CHF2.43
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Kuros Biosciences.

DB:YTSN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SWX:KURN Share Price ÷ EPS (both in CHF)

= 2.43 ÷ -1.34

-1.81x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kuros Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Kuros Biosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Kuros Biosciences's expected growth come at a high price?
Raw Data
DB:YTSN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.81x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
1.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Kuros Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Kuros Biosciences's assets?
Raw Data
DB:YTSN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in CHF CHF5.08
SWX:KURN Share Price * SWX (2019-04-18) in CHF CHF2.43
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:YTSN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SWX:KURN Share Price ÷ Book Value per Share (both in CHF)

= 2.43 ÷ 5.08

0.48x

* Primary Listing of Kuros Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Kuros Biosciences is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Kuros Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Kuros Biosciences has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Kuros Biosciences expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
1.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Kuros Biosciences expected to grow at an attractive rate?
  • Unable to compare Kuros Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Kuros Biosciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Kuros Biosciences's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:YTSN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:YTSN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 1.3%
DB:YTSN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 55.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:YTSN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in CHF Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:YTSN Future Estimates Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 54 -11 -6 1
2022-12-31 27 -18 -16 1
2021-12-31 13 -22 -21 1
2020-12-31 4 -15 -15 2
2019-12-31 2 -14 -14 2
DB:YTSN Past Financials Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -13 -12
2018-09-30 0 -13 -13
2018-06-30 0 -12 -15
2018-03-31 0 -11 -16
2017-12-31 1 -11 -16
2017-09-30 1 -10 -15
2017-06-30 1 -10 -13
2017-03-31 1 -10 -17
2016-12-31 1 -9 -20
2016-09-30 1 -7 -19
2016-06-30 1 -6 -18
2016-03-31 1 -4 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Kuros Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Kuros Biosciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:YTSN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Kuros Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:YTSN Future Estimates Data
Date (Data in CHF Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.34 -0.34 -0.34 1.00
2022-12-31 -0.82 -0.82 -0.82 1.00
2021-12-31 -1.09 -1.09 -1.09 1.00
2020-12-31 -0.95 -0.90 -1.00 2.00
2019-12-31 -0.97 -0.70 -1.24 2.00
DB:YTSN Past Financials Data
Date (Data in CHF Millions) EPS *
2018-12-31 -1.34
2018-09-30 -1.57
2018-06-30 -1.82
2018-03-31 -2.05
2017-12-31 -2.32
2017-09-30 -2.35
2017-06-30 -2.37
2017-03-31 -3.11
2016-12-31 -3.95
2016-09-30 -4.20
2016-06-30 -4.53
2016-03-31 -3.93

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Kuros Biosciences will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Kuros Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Kuros Biosciences has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Kuros Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Kuros Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Kuros Biosciences does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Kuros Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Kuros Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Kuros Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Kuros Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:YTSN Past Revenue, Cash Flow and Net Income Data
Date (Data in CHF Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.72 -11.69 8.93
2018-09-30 0.49 -13.23 10.76
2018-06-30 0.27 -14.76 12.58
2018-03-31 0.40 -15.62 13.91
2017-12-31 0.53 -16.48 15.24
2017-09-30 0.54 -14.97 14.09
2017-06-30 0.54 -13.46 12.94
2017-03-31 0.80 -16.60 15.01
2016-12-31 1.06 -19.74 17.07
2016-09-30 1.12 -18.66 15.43
2016-06-30 1.17 -17.58 13.78
2016-03-31 0.66 -11.68 8.82
2015-12-31 0.14 -5.78 3.85

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Kuros Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Kuros Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Kuros Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Kuros Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Kuros Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Kuros Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Kuros Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Kuros Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Kuros Biosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Kuros Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Kuros Biosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Kuros Biosciences Company Filings, last reported 3 months ago.

DB:YTSN Past Debt and Equity Data
Date (Data in CHF Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 76.48 0.00 18.33
2018-09-30 76.48 0.00 18.33
2018-06-30 68.70 0.00 9.65
2018-03-31 68.70 0.00 9.65
2017-12-31 73.14 0.00 16.67
2017-09-30 73.14 0.00 16.67
2017-06-30 77.65 0.00 21.42
2017-03-31 77.65 0.00 21.42
2016-12-31 38.32 0.00 12.37
2016-09-30 38.32 0.00 12.37
2016-06-30 42.95 0.00 17.45
2016-03-31 42.95 0.00 17.45
2015-12-31 10.44 3.70 15.94
  • Kuros Biosciences has no debt.
  • Kuros Biosciences currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Kuros Biosciences has sufficient cash runway for 1.4 years based on current free cash flow.
  • Kuros Biosciences has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 39.3% each year.
X
Financial health checks
We assess Kuros Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Kuros Biosciences has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Kuros Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Kuros Biosciences dividends.
If you bought €2,000 of Kuros Biosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Kuros Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Kuros Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:YTSN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:YTSN Future Dividends Estimate Data
Date (Data in CHF) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Kuros Biosciences has not reported any payouts.
  • Unable to verify if Kuros Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Kuros Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Kuros Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Kuros Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Kuros Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Kuros Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Kuros Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joost de Bruijn
AGE 52
TENURE AS CEO 1.3 years
CEO Bio

Prof. Joost D. de Bruijn, B.Sc. Ph.D., has been Chief Executive Officer of Kuros Biosciences AG since December 4, 2017 and its Director since June 14, 2018. Prof. Dr. de Bruijn served as the Chief Executive Officer and President of Xpand biotechnology BV until 2017. Prof. Dr. de Bruijn Founded Xpand Biotechnology BV in 2004. Mr. de Bruijn is Co-Owner of Aldabra B.V. He founded Progentix Orthobiology B.V. in 2004 and served as its Chief Executive Officer and President. He directed the Bone Tissue Engineering programme at IsoTis SA and showing safety of the technology in feasibility clinical trials. He has more than 28 years experience in academia and the life science industry. He has ample experience in bone tissue engineering, adult stem cell culturing techniques and the development of calcium phosphate scaffolds. He holds the Chair in Biomaterials at the Department of Materials of Queen Mary University of London, UK. He also holds the positions of professor of biomaterials at Queen Mary University of London (UK) and professor of regenerative medicine and entrepreneurship at Twente University (NL). He has published 165 papers in peer-reviewed journals and is the inventor of 24 patent families. He is scientific editor and reviewer for numerous international biomaterials, tissue engineering and regenerative medicine journals. He obtained his PhD from Leiden University in 1993, The Netherlands and spent part of his time at the Centre for Biomaterials, University of Toronto, Canada.

CEO Compensation
  • Insufficient data for Joost to compare compensation growth.
  • Insufficient data for Joost to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Kuros Biosciences management team in years:

1.3
Average Tenure
54
Average Age
  • The average tenure for the Kuros Biosciences management team is less than 2 years, this suggests a new team.
Management Team

Philippe Saudan

TITLE
Chief Development Officer
COMPENSATION
CHF383K
AGE
51
TENURE
2.7 yrs

Frank-Jan van der Velden

TITLE
Head of Business Affairs & Finance of Kuros Biosciences BV
COMPENSATION
CHF172K
AGE
59
TENURE
2.2 yrs

Joost de Bruijn

TITLE
CEO & Director
AGE
52
TENURE
1.3 yrs

Michael Grau

TITLE
Chief Financial Officer
AGE
56
TENURE
1.2 yrs

Oliver Kronenberg

TITLE
Senior Legal Counsel

Alistair Irvine

TITLE
Chief Business Officer
COMPENSATION
CHF2M
AGE
49

Pascal Longlade

TITLE
Chief Medical Officer
TENURE
0.6 yrs

Virginia Jamieson

TITLE
Consultant
AGE
65
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the Kuros Biosciences board of directors in years:

1.9
Average Tenure
52
Average Age
  • The average tenure for the Kuros Biosciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Clemens van Blitterswijk

TITLE
Chairman
COMPENSATION
CHF32K
TENURE
0.8 yrs

Joost de Bruijn

TITLE
CEO & Director
AGE
52
TENURE
0.8 yrs

Leanna Caron

TITLE
Vice Chairman of the Board
COMPENSATION
CHF64K
AGE
50

Gerhard Ries

TITLE
Director
COMPENSATION
CHF69K
AGE
49
TENURE
3.3 yrs

Cato Laurentin

TITLE
Member of Advisory Board

Ralph Müller

TITLE
Member of Advisory Board

Norbert Boos

TITLE
Member of Advisory Board

Thomas Steffen

TITLE
Member of Advisory Board

Chris Itin

TITLE
Director
COMPENSATION
CHF93K
AGE
54
TENURE
7.3 yrs

Giacomo Di Nepi

TITLE
Director
COMPENSATION
CHF36K
AGE
65
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Kuros Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Kuros Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the Kingdom of Saudi Arabia, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company’s synthetic orthobiologics pipeline products comprise MagnetOs Granules EU and MagnetOs Putty EU for the treatment of orthopedics, spinal, and dental problems; and MagnetOs Granules US and MagnetOs Putty US for the treatment of spinal fusion. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion; and KUR-112 that consists of a natural healing matrix combined with a targeted bone growth factor intended to be applied as a single percutaneous injection into solitary bone cysts. The company has collaborations with Checkmate Pharmaceuticals LLC for the licensing of CYT003 for the treatment of oncology; Pfizer Inc. to develop a novel anti-IgE vaccine; and Singapore’s Agency for Science, Technology and Research, which researches, develops, and commercializes an influenza vaccine. Kuros Biosciences AG was founded in 2000 and is headquartered in Schlieren, Switzerland.

Details
Name: Kuros Biosciences AG
YTSN
Exchange: DB
Founded: 2000
CHF32,090,956
15,058,611
Website: http://www.kuros.ch
Address: Kuros Biosciences AG
Wagistrasse 25,
Schlieren,
Zurich, 8952,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SWX KURN Common Shares SIX Swiss Exchange CH CHF 21. Jan 2016
OTCPK CSBT.F Common Shares Pink Sheets LLC US USD 21. Jan 2016
DB YTSN Common Shares Deutsche Boerse AG DE EUR 21. Jan 2016
LSE 0RHR Common Shares London Stock Exchange GB CHF 21. Jan 2016
Number of employees
Current staff
Staff numbers
35
Kuros Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 20:57
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/04/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.